References
Fisherman's Pulmonary Diseases & Disorders 5th ed
Murray & Nadel's Textbook of Respiratory Medicine 6th ed
Croatian & Douglas Respiratory Medicine 5th ed
Harrison's Principle of Internal Medicine 19th edition
NEJM Article
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology characterized by non-caseating granulomas. It most commonly affects the lungs presenting as bilateral hilar lymphadenopathy and pulmonary infiltrates. Extrapulmonary involvement can include the skin, eyes, liver and musculoskeletal system. Diagnosis involves clinical features and exclusion of other causes. Treatment involves corticosteroids while prognosis depends on organ involvement with lung fibrosis carrying the worst prognosis.
This document provides an overview of sarcoidosis, including:
- It is a multisystem granulomatous disorder of unknown cause that commonly affects the lungs, skin and eyes.
- Risk factors include genetics and environmental exposures, and it has the highest rates in the United States and Sweden.
- Clinical presentation varies from asymptomatic to involvement of multiple organ systems. Lung involvement is most common and is staged based on chest x-ray findings.
- Diagnosis involves ruling out other causes and may include biopsy showing non-caseating granulomas. Treatment involves corticosteroids and prognosis is generally good with many experiencing remission.
Pulmonary sarcoidosis is a multisystem inflammatory disease of unknown etiology characterized by non-caseating granulomas. It most commonly affects the lungs, skin, eyes and lymph nodes. The pathogenesis involves accumulation of inflammatory cells and T lymphocytes forming granulomas that can damage tissues. Diagnosis is based on clinical features, radiological evidence of non-caseating granulomas on biopsy with other causes excluded. Treatment depends on severity and organ involvement but may include corticosteroids.
Sarcoidosis is a multisystem disorder characterized by noncaseating granulomas in affected tissues. It most commonly involves the lungs but can affect other organs. The cause is unknown but genetic and environmental factors are thought to play a role. Diagnosis is made through biopsy showing granulomas and excluding other causes. Treatment involves corticosteroids for organ involvement. Prognosis is generally good with remission occurring within 3 years for over half of patients.
- A 41-year-old African American woman presents with a rash on her arm and worsening asthma symptoms over the past month. Biopsy of the rash shows noncaseating granulomas, and chest imaging reveals bilateral interstitial lung disease.
- Sarcoidosis is suspected based on the clinical findings and biopsy results. Sarcoidosis is a multisystem inflammatory disease characterized by the formation of noncaseating granulomas that can affect multiple organ systems, most commonly the lungs.
- Further workup and management are needed to evaluate organ involvement and determine treatment for the patient's sarcoidosis.
Sarcoidosis is a systemic granulomatous disease of unknown origin characterized by non-caseating granulomas that commonly affect the lungs. Pulmonary manifestations are present in 90% of patients and include bilateral hilar lymphadenopathy and pulmonary infiltrates. While two thirds of patients experience remission within ten years, one third have progressive disease that can lead to pulmonary fibrosis and, in rare cases, death. Computed tomography is more sensitive than chest x-rays in detecting lymph node enlargement and lung abnormalities associated with sarcoidosis.
This document provides information on sarcoidosis, a multisystem chronic inflammatory disease characterized by non-caseating granulomas. It discusses the epidemiology, etiology, clinical presentation, pathology, diagnosis and systems involvement of the disease. Sarcoidosis most commonly affects the lungs and lymph nodes, presenting as bilateral hilar lymphadenopathy. The cause is unknown but believed to involve a disordered immune response in genetically predisposed individuals. Diagnosis is based on clinical features along with identification of non-caseating granulomas in biopsy specimens.
Prof. Md. Khairul Hassan Jessy
Professor of Respiratory Medicine
National Institute of Diseases of the Chest and Hospital (NIDCH)
Mohakhali, Dhaka, Bangladesh
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology characterized by non-caseating granulomas. It most commonly affects the lungs presenting as bilateral hilar lymphadenopathy and pulmonary infiltrates. Extrapulmonary involvement can include the skin, eyes, liver and musculoskeletal system. Diagnosis involves clinical features and exclusion of other causes. Treatment involves corticosteroids while prognosis depends on organ involvement with lung fibrosis carrying the worst prognosis.
This document provides an overview of sarcoidosis, including:
- It is a multisystem granulomatous disorder of unknown cause that commonly affects the lungs, skin and eyes.
- Risk factors include genetics and environmental exposures, and it has the highest rates in the United States and Sweden.
- Clinical presentation varies from asymptomatic to involvement of multiple organ systems. Lung involvement is most common and is staged based on chest x-ray findings.
- Diagnosis involves ruling out other causes and may include biopsy showing non-caseating granulomas. Treatment involves corticosteroids and prognosis is generally good with many experiencing remission.
Pulmonary sarcoidosis is a multisystem inflammatory disease of unknown etiology characterized by non-caseating granulomas. It most commonly affects the lungs, skin, eyes and lymph nodes. The pathogenesis involves accumulation of inflammatory cells and T lymphocytes forming granulomas that can damage tissues. Diagnosis is based on clinical features, radiological evidence of non-caseating granulomas on biopsy with other causes excluded. Treatment depends on severity and organ involvement but may include corticosteroids.
Sarcoidosis is a multisystem disorder characterized by noncaseating granulomas in affected tissues. It most commonly involves the lungs but can affect other organs. The cause is unknown but genetic and environmental factors are thought to play a role. Diagnosis is made through biopsy showing granulomas and excluding other causes. Treatment involves corticosteroids for organ involvement. Prognosis is generally good with remission occurring within 3 years for over half of patients.
- A 41-year-old African American woman presents with a rash on her arm and worsening asthma symptoms over the past month. Biopsy of the rash shows noncaseating granulomas, and chest imaging reveals bilateral interstitial lung disease.
- Sarcoidosis is suspected based on the clinical findings and biopsy results. Sarcoidosis is a multisystem inflammatory disease characterized by the formation of noncaseating granulomas that can affect multiple organ systems, most commonly the lungs.
- Further workup and management are needed to evaluate organ involvement and determine treatment for the patient's sarcoidosis.
Sarcoidosis is a systemic granulomatous disease of unknown origin characterized by non-caseating granulomas that commonly affect the lungs. Pulmonary manifestations are present in 90% of patients and include bilateral hilar lymphadenopathy and pulmonary infiltrates. While two thirds of patients experience remission within ten years, one third have progressive disease that can lead to pulmonary fibrosis and, in rare cases, death. Computed tomography is more sensitive than chest x-rays in detecting lymph node enlargement and lung abnormalities associated with sarcoidosis.
This document provides information on sarcoidosis, a multisystem chronic inflammatory disease characterized by non-caseating granulomas. It discusses the epidemiology, etiology, clinical presentation, pathology, diagnosis and systems involvement of the disease. Sarcoidosis most commonly affects the lungs and lymph nodes, presenting as bilateral hilar lymphadenopathy. The cause is unknown but believed to involve a disordered immune response in genetically predisposed individuals. Diagnosis is based on clinical features along with identification of non-caseating granulomas in biopsy specimens.
Prof. Md. Khairul Hassan Jessy
Professor of Respiratory Medicine
National Institute of Diseases of the Chest and Hospital (NIDCH)
Mohakhali, Dhaka, Bangladesh
Sarcoidosis is a multisystem disorder characterized by noncaseating granulomatous inflammation that can affect any organ but most commonly involves the lungs and intrathoracic lymph nodes. It has an unknown etiology but is thought to be triggered by exposure to microbial agents in genetically susceptible individuals. The pathology shows noncaseating epithelioid cell granulomas. It has variable presentation based on ethnicity and geography. Acute sarcoidosis may present with erythema nodosum while chronic sarcoidosis can lead to pulmonary fibrosis over two years.
Sarcoidosis is a multisystem disorder characterized by non-caseating granulomas that commonly affect the lungs and lymph nodes. It most often occurs in adults under 40 years old and has a higher prevalence in African Americans. While the exact cause is unknown, it involves an abnormal immune response in genetically predisposed individuals. Lung involvement is present in 90% of cases and lymph node involvement in 70% of cases. Pulmonary sarcoidosis ranges from asymptomatic hilar lymphadenopathy to progressive pulmonary fibrosis. Skin and eye involvement also occurs in a significant portion of patients.
This document discusses idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis. It provides the revised ATS/ERS classification of idiopathic interstitial pneumonias and describes non-specific interstitial pneumonia (NSIP) and cryptogenic organizing pneumonia (COP) in detail. NSIP is characterized by a uniform pattern of interstitial inflammation and fibrosis. It commonly occurs in connective tissue diseases and has a good prognosis with treatment. COP is defined by organizing pneumonia in the absence of an identifiable cause, and presents with patchy consolidations that are typically peripheral and migratory.
The document provides information on pulmonary aspergillosis, caused by inhalation of the Aspergillus fungus. It discusses the main disease entities: allergic bronchopulmonary aspergillosis (ABPA), aspergilloma, invasive aspergillosis, and chronic necrotizing pulmonary aspergillosis. ABPA involves hypersensitivity reactions in asthma/CF patients. Aspergilloma forms fungal balls in pre-existing lung cavities. Invasive aspergillosis mainly affects immunocompromised individuals and can disseminate. Chronic forms progress over months-years in patients with underlying lung disease. Clinical features, diagnosis, treatment and prognosis are outlined
This document provides information on sarcoidosis, a chronic inflammatory disease of unknown cause that most commonly affects the lungs. It discusses the typical presentation and involvement of organs, diagnostic testing including imaging and biopsy findings, differential diagnoses, prognosis, and treatment approaches including corticosteroids as first-line therapy and immunosuppressants for refractory disease. The goal of treatment is to control inflammation and symptoms, with corticosteroids being the mainstay but other agents used if there is no response or for life-threatening disease.
This document discusses sarcoidosis, a disease characterized by non-caseating granulomas in multiple organs. Key points:
- It most commonly involves the lungs and is more prevalent in women, especially in the 3rd and 6th decades of life.
- The cause is unknown but it involves an abnormal immune response mediated by T-cells and macrophages forming granulomas. Lung involvement is seen in over 90% of cases.
- Diagnosis involves clinical features, imaging showing hilar lymphadenopathy, elevated ACE levels in 60% of acute cases, and biopsy demonstrating non-caseating granulomas. Most patients see resolution within 2-5 years.
This document discusses sarcoidosis, a multisystem granulomatous disorder of unknown origin. It covers the history of sarcoidosis, epidemiology, pathology, organ involvement, staging, diagnosis and treatment. Specifically, it notes that sarcoidosis was first described in 1887 and causes non-caseating granulomas. It can affect many organs, especially the lungs, and has varying presentations depending on the organs involved. Diagnosis involves ruling out other causes and identifying characteristic granulomas on biopsy.
This document provides information on ANCA-Associated Vasculitis (AAV). It discusses the classification, epidemiology, clinical features, diagnosis and treatment of AAV. Key points include: AAV includes GPA, MPA, RLV and EGPA which are associated with ANCA antibodies; clinical manifestations can include ENT, lung, kidney, and skin involvement; diagnosis involves labs like ANCA testing and biopsies; and treatment involves immunosuppressive drugs like cyclophosphamide and rituximab for induction of remission.
This document discusses vasculitis, which is an inflammatory destruction of blood vessels. It can affect all ages but some types are restricted to certain groups. It has both genetic and environmental components. Symptoms vary depending on the size of vessels involved and can include fatigue, rashes, nerve problems, and organ damage. Diagnosis involves clinical features, lab tests, and sometimes biopsies. Treatment is usually with steroids and other immunosuppressants to induce and maintain remission. Complications can be serious if not treated properly.
1. The document outlines a 6 step approach to diagnosing and treating vasculitis.
2. Step 1 is to learn to recognize vasculitis based on common features like purpura, pulmonary infiltrates, glomerulonephritis.
3. Step 2 is to rule out secondary causes of vasculitis like infections, malignancies, drugs.
4. Step 3 involves determining the pattern of vessel involvement - large, medium, or small vessels.
This case describes a patient with limited scleroderma (CREST syndrome). Key features include:
- A 50-year-old female with CREST syndrome characterized by calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasias.
- She is positive for the autoantibody anti-centromere, which is seen in 70-80% of limited scleroderma/CREST syndrome cases.
- Her disease involves skin thickening distal to the elbows and knees (sclerodactyly), as well as gastrointestinal symptoms of esophageal dysmotility. She has minimal organ involvement typical of limited
Hypersensitivity pneumonitis (HP) is an interstitial lung disease caused by repeated inhalation and sensitization to various antigens. It affects the lung interstitium and has variable clinical presentations. Common causative agents include avian and microbial antigens. The immunopathogenesis involves both humoral and cellular immune responses. HP is classified as acute, subacute, or chronic based on clinical manifestations. Diagnosis relies on a history of antigen exposure, precipitating antibodies, clinical features, imaging, and pathology. Chest radiography and HRCT are important diagnostic tools, with HRCT showing findings like nodules, ground glass opacity, and fibrosis that vary depending on the disease stage.
This document provides information on sarcoidosis, including its definition, epidemiology, etiology, clinical presentation, complications, diagnosis, and management. Some key points:
- Sarcoidosis is a granulomatous disease involving multiple organ systems that is thought to be due to an abnormal immune response in genetically predisposed individuals.
- Lungs are involved in over 90% of cases. Other commonly involved organs include lymph nodes, eyes, and skin.
- Diagnosis is based on compatible clinical presentation plus histological evidence of non-caseating granulomas. Bronchoalveolar lavage can also provide supportive evidence.
- Treatment is usually not needed for asymptomatic cases but may involve cort
Allergic Bronchopulmonary Aspergillosis (ABPA) is an allergic pulmonary disorder caused by a hypersensitivity reaction to the fungus Aspergillus fumigatus. It occurs most commonly in people with asthma or cystic fibrosis. The pathogenesis involves an immune response to Aspergillus colonization in the airways leading to mucus plugging, bronchiectasis, and lung fibrosis. Diagnosis is based on criteria including asthma, positive skin test or serum IgE to Aspergillus, eosinophilia, elevated total serum IgE, and central bronchiectasis on chest imaging. Treatment involves systemic corticosteroids to suppress the immune response along with antifungal agents
Vasculitis refers to inflammation of blood vessels. This document discusses the pathophysiology, classification, clinical presentation, diagnosis, and treatment of various types of vasculitis. The main types include large vessel vasculitis (e.g. giant cell arteritis, Takayasu arteritis), medium vessel vasculitis (e.g. polyarteritis nodosa, Kawasaki disease), small vessel vasculitis (ANCA-associated vasculitis like granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), and immune complex small vessel vasculitis (e.g. IgA vasculitis, antiglomer
This document summarizes various connective tissue disease-associated interstitial lung diseases. It describes common intrathoracic manifestations and imaging findings for conditions like rheumatoid arthritis, progressive systemic sclerosis, systemic lupus erythematosus, and polymyositis/dermatomyositis. For each condition, it lists typical radiological patterns seen on CT such as ground glass opacities, reticulation, consolidation, and honeycombing. Photomicrographs are also included to illustrate histopathological findings for some of the interstitial lung diseases.
This document discusses various types of vasculitis and their ocular manifestations. It begins by describing the typical presentations of ocular vasculitis such as decreased vision, floaters, and scotomata. Imaging findings on fluorescein angiography and optical coherence tomography are also summarized. The document then differentiates between primary ocular vasculitis, secondary ocular vasculitis, and systemic vasculitis involving the eye. Specific conditions are outlined including Eale's disease, giant cell arteritis, Wegener's granulomatosis, and lupus retinopathy. Treatment options are briefly mentioned for some conditions.
This document discusses multisystem autoimmune disease, also known as systemic lupus erythematosus (SLE). SLE is characterized by the failure to maintain self-tolerance, resulting in an unpredictable and relapsing disease that commonly affects the skin, kidneys, serosal membranes, joints, and heart. Diagnosis requires 4 of several criteria during any observation period, and it is more common in women and black Americans. The pathogenesis involves abnormal self-reactive antibodies against nuclear and cytoplasmic antigens such as Sm/RNP and dsDNA. Complications can include renal disease, skin changes, splenic abnormalities, and Libman-Sacks endocarditis - characterized by nonbacterial vegetations in the heart
This document discusses hypereosinophillic syndrome (HES), which is defined as persistent eosinophilia with organ involvement. It outlines the biology of eosinophils and defines reactive vs idiopathic hypereosinophilia. HES can be classified as myeloproliferative- or lymphocytic-variant based on underlying cause. Common organ systems involved are heart, lungs, skin and nervous system. The document recommends investigations to identify underlying causes and excludes other conditions. It also discusses treatment options for HES, including corticosteroids and targeted therapies depending on the identified genetic abnormality or cytokine driving eosinophil production.
Sarcoidosis is a multisystem inflammatory disease characterized by noncaseating granulomas in affected tissues. It most commonly affects the lungs and lymph nodes. While the cause is unknown, genetic and environmental factors are thought to play a role. Diagnosis requires clinical signs, radiologic findings, and histologic evidence of granulomas. Treatment involves corticosteroids, with methotrexate and hydroxychloroquine as alternatives for refractory or extrapulmonary disease. Prognosis depends on organ involvement, with cardiac and neurological disease carrying the worst outcomes.
Sarcoidosis is a systemic granulomatous disease of unknown cause that most commonly involves the lungs and intrathoracic lymph nodes. It can affect any organ and presents variably from asymptomatic to acute symptoms like fever and weight loss. Lung involvement is common and is staged based on chest x-ray findings. Skin, eye, and musculoskeletal involvement also occur. The diagnosis involves ruling out other causes through biopsy showing non-caseating granulomas and clinical/radiological findings. Treatment focuses on symptomatic cases using steroids or immunosuppressants for severe or organ-threatening disease.
Sarcoidosis is a multisystem disorder characterized by noncaseating granulomatous inflammation that can affect any organ but most commonly involves the lungs and intrathoracic lymph nodes. It has an unknown etiology but is thought to be triggered by exposure to microbial agents in genetically susceptible individuals. The pathology shows noncaseating epithelioid cell granulomas. It has variable presentation based on ethnicity and geography. Acute sarcoidosis may present with erythema nodosum while chronic sarcoidosis can lead to pulmonary fibrosis over two years.
Sarcoidosis is a multisystem disorder characterized by non-caseating granulomas that commonly affect the lungs and lymph nodes. It most often occurs in adults under 40 years old and has a higher prevalence in African Americans. While the exact cause is unknown, it involves an abnormal immune response in genetically predisposed individuals. Lung involvement is present in 90% of cases and lymph node involvement in 70% of cases. Pulmonary sarcoidosis ranges from asymptomatic hilar lymphadenopathy to progressive pulmonary fibrosis. Skin and eye involvement also occurs in a significant portion of patients.
This document discusses idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis. It provides the revised ATS/ERS classification of idiopathic interstitial pneumonias and describes non-specific interstitial pneumonia (NSIP) and cryptogenic organizing pneumonia (COP) in detail. NSIP is characterized by a uniform pattern of interstitial inflammation and fibrosis. It commonly occurs in connective tissue diseases and has a good prognosis with treatment. COP is defined by organizing pneumonia in the absence of an identifiable cause, and presents with patchy consolidations that are typically peripheral and migratory.
The document provides information on pulmonary aspergillosis, caused by inhalation of the Aspergillus fungus. It discusses the main disease entities: allergic bronchopulmonary aspergillosis (ABPA), aspergilloma, invasive aspergillosis, and chronic necrotizing pulmonary aspergillosis. ABPA involves hypersensitivity reactions in asthma/CF patients. Aspergilloma forms fungal balls in pre-existing lung cavities. Invasive aspergillosis mainly affects immunocompromised individuals and can disseminate. Chronic forms progress over months-years in patients with underlying lung disease. Clinical features, diagnosis, treatment and prognosis are outlined
This document provides information on sarcoidosis, a chronic inflammatory disease of unknown cause that most commonly affects the lungs. It discusses the typical presentation and involvement of organs, diagnostic testing including imaging and biopsy findings, differential diagnoses, prognosis, and treatment approaches including corticosteroids as first-line therapy and immunosuppressants for refractory disease. The goal of treatment is to control inflammation and symptoms, with corticosteroids being the mainstay but other agents used if there is no response or for life-threatening disease.
This document discusses sarcoidosis, a disease characterized by non-caseating granulomas in multiple organs. Key points:
- It most commonly involves the lungs and is more prevalent in women, especially in the 3rd and 6th decades of life.
- The cause is unknown but it involves an abnormal immune response mediated by T-cells and macrophages forming granulomas. Lung involvement is seen in over 90% of cases.
- Diagnosis involves clinical features, imaging showing hilar lymphadenopathy, elevated ACE levels in 60% of acute cases, and biopsy demonstrating non-caseating granulomas. Most patients see resolution within 2-5 years.
This document discusses sarcoidosis, a multisystem granulomatous disorder of unknown origin. It covers the history of sarcoidosis, epidemiology, pathology, organ involvement, staging, diagnosis and treatment. Specifically, it notes that sarcoidosis was first described in 1887 and causes non-caseating granulomas. It can affect many organs, especially the lungs, and has varying presentations depending on the organs involved. Diagnosis involves ruling out other causes and identifying characteristic granulomas on biopsy.
This document provides information on ANCA-Associated Vasculitis (AAV). It discusses the classification, epidemiology, clinical features, diagnosis and treatment of AAV. Key points include: AAV includes GPA, MPA, RLV and EGPA which are associated with ANCA antibodies; clinical manifestations can include ENT, lung, kidney, and skin involvement; diagnosis involves labs like ANCA testing and biopsies; and treatment involves immunosuppressive drugs like cyclophosphamide and rituximab for induction of remission.
This document discusses vasculitis, which is an inflammatory destruction of blood vessels. It can affect all ages but some types are restricted to certain groups. It has both genetic and environmental components. Symptoms vary depending on the size of vessels involved and can include fatigue, rashes, nerve problems, and organ damage. Diagnosis involves clinical features, lab tests, and sometimes biopsies. Treatment is usually with steroids and other immunosuppressants to induce and maintain remission. Complications can be serious if not treated properly.
1. The document outlines a 6 step approach to diagnosing and treating vasculitis.
2. Step 1 is to learn to recognize vasculitis based on common features like purpura, pulmonary infiltrates, glomerulonephritis.
3. Step 2 is to rule out secondary causes of vasculitis like infections, malignancies, drugs.
4. Step 3 involves determining the pattern of vessel involvement - large, medium, or small vessels.
This case describes a patient with limited scleroderma (CREST syndrome). Key features include:
- A 50-year-old female with CREST syndrome characterized by calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasias.
- She is positive for the autoantibody anti-centromere, which is seen in 70-80% of limited scleroderma/CREST syndrome cases.
- Her disease involves skin thickening distal to the elbows and knees (sclerodactyly), as well as gastrointestinal symptoms of esophageal dysmotility. She has minimal organ involvement typical of limited
Hypersensitivity pneumonitis (HP) is an interstitial lung disease caused by repeated inhalation and sensitization to various antigens. It affects the lung interstitium and has variable clinical presentations. Common causative agents include avian and microbial antigens. The immunopathogenesis involves both humoral and cellular immune responses. HP is classified as acute, subacute, or chronic based on clinical manifestations. Diagnosis relies on a history of antigen exposure, precipitating antibodies, clinical features, imaging, and pathology. Chest radiography and HRCT are important diagnostic tools, with HRCT showing findings like nodules, ground glass opacity, and fibrosis that vary depending on the disease stage.
This document provides information on sarcoidosis, including its definition, epidemiology, etiology, clinical presentation, complications, diagnosis, and management. Some key points:
- Sarcoidosis is a granulomatous disease involving multiple organ systems that is thought to be due to an abnormal immune response in genetically predisposed individuals.
- Lungs are involved in over 90% of cases. Other commonly involved organs include lymph nodes, eyes, and skin.
- Diagnosis is based on compatible clinical presentation plus histological evidence of non-caseating granulomas. Bronchoalveolar lavage can also provide supportive evidence.
- Treatment is usually not needed for asymptomatic cases but may involve cort
Allergic Bronchopulmonary Aspergillosis (ABPA) is an allergic pulmonary disorder caused by a hypersensitivity reaction to the fungus Aspergillus fumigatus. It occurs most commonly in people with asthma or cystic fibrosis. The pathogenesis involves an immune response to Aspergillus colonization in the airways leading to mucus plugging, bronchiectasis, and lung fibrosis. Diagnosis is based on criteria including asthma, positive skin test or serum IgE to Aspergillus, eosinophilia, elevated total serum IgE, and central bronchiectasis on chest imaging. Treatment involves systemic corticosteroids to suppress the immune response along with antifungal agents
Vasculitis refers to inflammation of blood vessels. This document discusses the pathophysiology, classification, clinical presentation, diagnosis, and treatment of various types of vasculitis. The main types include large vessel vasculitis (e.g. giant cell arteritis, Takayasu arteritis), medium vessel vasculitis (e.g. polyarteritis nodosa, Kawasaki disease), small vessel vasculitis (ANCA-associated vasculitis like granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), and immune complex small vessel vasculitis (e.g. IgA vasculitis, antiglomer
This document summarizes various connective tissue disease-associated interstitial lung diseases. It describes common intrathoracic manifestations and imaging findings for conditions like rheumatoid arthritis, progressive systemic sclerosis, systemic lupus erythematosus, and polymyositis/dermatomyositis. For each condition, it lists typical radiological patterns seen on CT such as ground glass opacities, reticulation, consolidation, and honeycombing. Photomicrographs are also included to illustrate histopathological findings for some of the interstitial lung diseases.
This document discusses various types of vasculitis and their ocular manifestations. It begins by describing the typical presentations of ocular vasculitis such as decreased vision, floaters, and scotomata. Imaging findings on fluorescein angiography and optical coherence tomography are also summarized. The document then differentiates between primary ocular vasculitis, secondary ocular vasculitis, and systemic vasculitis involving the eye. Specific conditions are outlined including Eale's disease, giant cell arteritis, Wegener's granulomatosis, and lupus retinopathy. Treatment options are briefly mentioned for some conditions.
This document discusses multisystem autoimmune disease, also known as systemic lupus erythematosus (SLE). SLE is characterized by the failure to maintain self-tolerance, resulting in an unpredictable and relapsing disease that commonly affects the skin, kidneys, serosal membranes, joints, and heart. Diagnosis requires 4 of several criteria during any observation period, and it is more common in women and black Americans. The pathogenesis involves abnormal self-reactive antibodies against nuclear and cytoplasmic antigens such as Sm/RNP and dsDNA. Complications can include renal disease, skin changes, splenic abnormalities, and Libman-Sacks endocarditis - characterized by nonbacterial vegetations in the heart
This document discusses hypereosinophillic syndrome (HES), which is defined as persistent eosinophilia with organ involvement. It outlines the biology of eosinophils and defines reactive vs idiopathic hypereosinophilia. HES can be classified as myeloproliferative- or lymphocytic-variant based on underlying cause. Common organ systems involved are heart, lungs, skin and nervous system. The document recommends investigations to identify underlying causes and excludes other conditions. It also discusses treatment options for HES, including corticosteroids and targeted therapies depending on the identified genetic abnormality or cytokine driving eosinophil production.
Sarcoidosis is a multisystem inflammatory disease characterized by noncaseating granulomas in affected tissues. It most commonly affects the lungs and lymph nodes. While the cause is unknown, genetic and environmental factors are thought to play a role. Diagnosis requires clinical signs, radiologic findings, and histologic evidence of granulomas. Treatment involves corticosteroids, with methotrexate and hydroxychloroquine as alternatives for refractory or extrapulmonary disease. Prognosis depends on organ involvement, with cardiac and neurological disease carrying the worst outcomes.
Sarcoidosis is a systemic granulomatous disease of unknown cause that most commonly involves the lungs and intrathoracic lymph nodes. It can affect any organ and presents variably from asymptomatic to acute symptoms like fever and weight loss. Lung involvement is common and is staged based on chest x-ray findings. Skin, eye, and musculoskeletal involvement also occur. The diagnosis involves ruling out other causes through biopsy showing non-caseating granulomas and clinical/radiological findings. Treatment focuses on symptomatic cases using steroids or immunosuppressants for severe or organ-threatening disease.
Sarcoidosis is a systemic granulomatous disease of unknown cause that commonly involves the lungs. It occurs worldwide and is characterized by the formation of non-caseating granulomas in affected organs. While the cause is unknown, it is believed to involve a dysregulated immune response in genetically susceptible individuals. Clinical manifestations vary depending on the organs involved but commonly include respiratory symptoms as well as skin and eye lesions. Diagnosis involves clinical and radiological evidence of granulomatous inflammation along with exclusion of other potential causes. Prognosis is generally good with many patients experiencing resolution of symptoms within a few years.
Sjögren syndrome primarily affects women in their 40s-50s and is characterized by dry eyes and dry mouth due to reduced tear and saliva production. It has a variety of systemic manifestations involving organs like lungs, kidneys, blood vessels, and nerves. Diagnosis involves tests of tear and saliva function along with labial gland biopsy showing lymphocytic infiltrates. Treatment focuses on symptom relief and immunosuppression for severe extraglandular disease.
Sarcoidosis is a chronic inflammatory disease characterized by the formation of non-caseating granulomas in multiple organs, most commonly affecting the lungs. It has unknown causes but is thought to involve genetic and environmental factors. Historically, it was first described in the skin in 1899 and was later found to also affect the lungs and lymph nodes. It presents variably from being asymptomatic to causing respiratory symptoms or lesions in other organs. Diagnosis involves clinical features, chest imaging typically showing bilateral hilar lymphadenopathy, and biopsy demonstrating granulomas. Treatment involves observation of asymptomatic cases but corticosteroids for symptomatic or progressive disease. Prognosis is generally good with many cases resolving spontaneously but advanced lung fibrosis can occasionally occur
Scleroderma is an autoimmune connective tissue disease that causes hardening of the skin and internal organs. It is classified into limited and diffuse subtypes based on the extent of skin involvement. Raynaud's phenomenon, skin thickening, and pulmonary and gastrointestinal issues are common clinical manifestations. The underlying pathogenesis involves vascular dysfunction, immune dysregulation, and fibrosis. Management focuses on treating individual organ system complications. Prognosis depends on the specific organ systems affected and can range from relatively mild to severe with significant morbidity and mortality.
This document provides a review of neurosarcoidosis. It begins with defining sarcoidosis and neurosarcoidosis as involving non-caseating granulomas in the nervous system. It then discusses the epidemiology, clinical manifestations such as cranial neuropathies and meningitis, diagnostic criteria including biopsy evidence, and treatment primarily with corticosteroids. The review concludes with highlighting the challenges of diagnosing and managing neurosarcoidosis given the lack of randomized controlled trials and importance of raising awareness of this condition.
This document summarizes information about cryptococcosis, an infection caused by the fungi Cryptococcus neoformans and Cryptococcus gattii. It begins with a clinical case of a 31-year-old woman with cryptococcal meningitis. It then provides background on the microbiology, epidemiology, pathogenesis, clinical presentation, investigations including India ink staining and antigen testing, imaging findings, and standard treatment recommendations of 14 days of IV amphotericin B and fluconazole for induction therapy followed by 8 weeks of fluconazole consolidation therapy.
This document provides an overview of sarcoidosis, with a focus on its ocular manifestations and diagnosis. Some key points:
- Sarcoidosis is a chronic inflammatory disease characterized by non-caseating granulomas that commonly affect the lungs, lymph nodes, eyes, and skin.
- Ocular involvement occurs in 40% of sarcoidosis patients, usually presenting as chronic, bilateral granulomatous uveitis. This can manifest as anterior uveitis, intermediate uveitis, posterior uveitis, or a combination.
- Complications of ocular sarcoidosis include glaucoma, cataracts, cystoid macular edema, choroidal granulo
This document provides information on cryptococcosis, caused by the fungi Cryptococcus neoformans and Cryptococcus gattii. It discusses the clinical case of a 31-year-old HIV+ female presenting with confusion and other symptoms. The diagnosis was determined to be cryptococcal meningitis based on CSF analysis showing yeast cells and a positive India ink test. Background information is then given on the microbiology, epidemiology, pathogenesis, clinical presentation and investigations for cryptococcosis. Standard treatment in Botswana involves initial intravenous amphotericin B and fluconazole followed by oral fluconazole consolidation therapy.
Sarcoidosis is a multisystem granulomatous disease that commonly affects the lungs, skin, and lymph nodes. It causes non-caseating granulomas and can involve multiple organs including the eyes. Ocular involvement occurs in about 26% of chronic cases and most commonly manifests as chronic granulomatous anterior uveitis with mutton-fat keratic precipitates, iris nodules, and secondary glaucoma or cataracts. Posterior segment involvement such as choroidal or retinal lesions may also occur. The etiology is unknown but appears to involve an abnormal immune response triggered by environmental antigens in genetically susceptible individuals. Diagnosis requires biopsy demonstrating non-caseating granulomas and treatment
This document discusses the diagnosis of interstitial lung disease (ILD). It defines ILD as a collection of over 100 lung disorders that share clinical, radiographic, and pathological features. ILD is classified based on patterns seen on histology and radiography. Risk factors include age, smoking, occupation, and family history. Signs and symptoms include dyspnea, cough, chest pain, and digital clubbing. Diagnostic tests involve pulmonary function tests, chest imaging like HRCT, bronchoscopy, and surgical lung biopsy. HRCT is more sensitive than chest x-rays and can identify patterns like ground glass opacities and cysts that indicate different diseases.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect various organs in the body. Common symptoms include fatigue, joint pain, rashes, and kidney problems. It is caused by genetic and environmental factors that lead to abnormal immune responses against the body's own tissues. Diagnosis involves evaluating clinical features along with blood tests to detect autoantibodies. Treatment depends on the specific organs involved but may include medications to suppress the immune system.
Transmissible spongiform encephalopathies (TSEs) are a group of fatal neurodegenerative disorders caused by prions. Prions are abnormally folded forms of a normal cellular protein that are highly resistant to destruction and can transmit their abnormal shape to other normal proteins. TSEs affect both humans and animals. Some examples include Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE, or "mad cow disease") in cattle, and chronic wasting disease in deer. Prion diseases have long incubation periods, are always fatal, and currently have no treatment or cure.
This document provides an overview of interstitial lung disease (ILD), also known as diffuse parenchymal lung disease. It discusses the epidemiology, diagnostic approach, classification, and treatment of ILD. The diagnostic approach involves obtaining a thorough history, physical exam, pulmonary function tests, imaging like chest X-rays and HRCT, and tissue sampling via bronchoscopy or surgical lung biopsy. ILDs can be classified as idiopathic interstitial pneumonias, granulomatous diseases like sarcoidosis, connective tissue disease-associated, and those related to occupational or environmental exposures. Treatment depends on the underlying cause but may include immunosuppression, antifibrotic drugs, managing comorbid
This document discusses surgical infections of the thorax, including pathology, investigations, treatments, and specific conditions. It covers topics such as the stages of empyema (exudative, fibrino purulent, organizing), classifications of inflammatory diseases of the thorax (infections of the container vs contents), and treatments for specific infections like tuberculosis of the ribs and actinomycosis. Empyema treatment options discussed include antibiotics, tube thoracostomy, fibrinolytic therapy, VATS, rib resection, decortication, and thoracoplasty.
Orbital cellulitis is an inflammatory condition affecting the tissues behind the orbital septum. It typically presents with eyelid swelling and redness, vision loss, and pain with eye movement. The most common causes are sinus infections or infections of nearby structures that spread. Prompt diagnosis and treatment with antibiotics and imaging such as CT are important to prevent complications like abscesses or intracranial infections. Surgical drainage may be needed for abscesses. With appropriate treatment, outcomes have improved but orbital cellulitis still poses risks if not addressed quickly.
This document discusses sexually transmitted infections (STIs) caused by Treponema pallidum (syphilis), Neisseria gonorrhoeae (gonorrhea), and Chlamydia trachomatis (chlamydia). It describes the clinical manifestations of primary, secondary, and late syphilis. It also discusses gonococcal and chlamydial infections in males and females, including urethritis, cervicitis, pelvic inflammatory disease, and disseminated gonococcal infection. The document provides details on laboratory testing, treatment, and clinical presentation of these common STIs.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
- Video recording of this lecture in English language: https://youtu.be/RvdYsTzgQq8
- Video recording of this lecture in Arabic language: https://youtu.be/ECILGWtgZko
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
2. Sarcoidosis is a multisystem inflammatory
disease of unknown etiology that predominantly
affects the lungs and intrathoracic lymph nodes.
•Sarc-oid-osis
•sarc - flesh,
•oid - like
•osis - diseased or abnormal condition
3.
4. Sarcoidosis is manifested by the
presence of discrete
noncaseating epithelloid
granulomas (NCGs) in affected
organ tissues.
5. The modern history of sarcoidosis
• In 1899, the pioneering Norwegian dermatologist
Caesar Boeck describe skin nodules characterized by
compact, sharply defined foci of "epithelioid cells with
large pale nuclei and also a few giant cells .
• Thinking this resembled sarcoma, he called the
condition "multiple benign sarcoid of the skin.
6. All racial .
All ethnic groups. (16x >> in
blacks)
All ages (with the incidence peaking at 20 to
39 years).
F:M ratio 2:1.
Genetic : monozygotic:dizygotic
twins= 13:1
7.
8. The incidence
• The highest annual incidence in northern European
countries 5 - 40 / 100,000.
• In Japan, the annual incidence 1 - 2 / 100,000.
• Among black Americans is roughly 3 times that
among white Americans (35.5 / 100,000, as compared
with 10.9 / 100,000.
• India: sarcoidosis constituted 10 to 12 cases/1,000
new registrations annually at a Respiratory Unit at
Kolkata and 61.2/100,000 new cases seen at
theVallabhbhai Patel Chest Institute (VPCI), Delhi
16. The cause of sarcoidosis is
unknown.
Efforts to identify a possible
infectious etiology have been
unsuccessful.
17. Genetic and environmental factors seem to play a role.
As yet, no bacterial, fungal, or viral antigen has been
consistently isolated from the sarcoidosis lesions.
Sarcoidosis is neither a malignant nor an autoimmune
disease.
18. The following have been suggested as
possible candidates that might play a role in
causing sarcoidosis:
• Mycobacteria, such as Mycobacterium tuberculosis, and
atypical pathogens have been suggested. mKatG protein.
• Fungi and viruses, particularly Mycoplasma, Chlamydia,
and Epstein-Barr virus, have been unconvincingly
implicated.
19. Environmental Causes
• Some of the earliest studies of sarcoidosis reported
associations with exposures to irritants found in rural
settings, such as emissions from wood-burning stoves
and tree pollen.
• More recently, associations with sarcoidosis and
exposure to inorganic particles ,insecticides ,and
moldy environments have been reported.
• Occupational studies have shown positive associations
with service in the U.S. Navy ,metalworking ,
firefighting ,and the handling of building supplies.
20. Genetic Features
• Familial sarcoidosis was first reported in 1923 in
two affected sisters .
• No formal twin study has been reported, but the
concordance appears to be higher in
monozygotic twins than in dizygotic twins .
• In A Case-Control Study, patients with
sarcoidosis stated 5 times as often as control
subjects that they had siblings or parents with
sarcoidosis.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31. • Presentation depends on the extent and severity
of the organ involved.
• Approximately 5% of cases are asymptomatic
and incidentally detected by CXR.
• Systemic symptoms occur in 45% of cases such
as :
• Fever.
• anorexia
• Fatigue.
• Night sweats .
• Weight loss .
• Pulmonary, dyspnea on exertion, cough, chest
pain, and hemoptysis (rare) occur in 50% of
cases.
36. Sarcoidal granulomas can involve any organ, but in
more than 90% of patients, clinical sarcoidosis is
manifested as
pulmonary involvement
intrathoracic LN enlargement,
skin or
ocular signs and symptoms, or some combination of
these findings.
Organ Involvement
37. Pulmonary Involvement
• Dyspnea, Cough, Vague chest discomfort, and Wheezing.
• Chest radiographs in patients with sarcoidosis have been classified into four
stages:
• Stage 1, bilateral hilar lymphadenopathy without infiltration.
• Stage 2, bilateral hilar lymphadenopathy with infiltration.
• Stage 3, infiltration alone.
• Stage 4, fibrotic bands, bullae, hilar retraction, bronchiectasis, and diaphragmatic tenting.
• These so-called stages represent radiographic patterns and do not indicate
disease chronicity or correlate with changes in pulmonary function.
38. Cutaneous Involvement
Although not life-threatening, but can be
emotionally devastating.
• Erythema nodosum may occur.
• Lupus pernio is the most specific associated cutaneous lesion.
• Violaceous rash is often seen on the cheeks or nose.
• Osseous involvement may be present.
• Maculopapular plaques are possible.
• Lupus pernio is more common in women than in men and is associated
with chronic disease and extrapulmonary involvement.
• Erythema nodosum occurs in about 10% of patients with sarcoidosis
and usually lasts for about 3 weeks.
• Biopsy specimens of erythema nodosum lesions show nonspecific septal
panniculitis, which neither confirms nor negates the diagnosis of
sarcoidosis.
39.
40.
41. Liver and Spleen Involvement
• 10% of all patients with sarcoidosis have elevated serum
aminotransferase and alkaline phosphatase levels.
• A cholestatic syndrome characterized by pruritus and
jaundice, hepatic failure, or portal hypertension can
develop (liver involvement is usually clinically silent).
• Detection of hepatic and splenic lesions on CT is
described in 5% and 15% of patients.
• 60% of patients with hepatic manifestations of sarcoidosis
have constitutional symptoms such as fever, night
sweats, anorexia, and weight loss.
• Portal hypertension with variceal bleeding, a
hepatopulmonary syndrome with refractory hypoxemia,
and cirrhosis leading to liver failure occur in only 1% of
patients with sarcoidosis.
42. Neurologic Involvement
• CNS is involved in up to 25% of patients with sarcoidosis who undergo
autopsy, but only 10% of all patients with sarcoidosis present with
neurologic symptoms.
• The most common problems:
• cranial-nerve palsies.
• Headache.
• Ataxia.
• cognitive dysfunction.
• Weakness.
• seizures.
• CSF Analysis :
• nonspecific lymphocytic inflammation.
• measuring ACE levels .
• oligoclonal immunoglobulin bands in the CSF are elevated, making it difficult
to differentiate sarcoidosis from multiple sclerosis.
• Magnetic resonance imaging (MRI)
43. Ophthalmologic
Complications
• The eye and adnexa are involved in 25 -80% of
patients with sarcoidosis,this necessitating
routine slit-lamp and funduscopic examination.
• Anterior or posterior granulomatous uveitis .
• Conjunctival lesions and scleral plaques may
also be noted.
• Ocular involvement may lead to blindness if
untreated.
• Anterior uveitis
(is the most common manifestation)
chronic anterior uveitis, with insidious symptoms leading
to glaucoma and vision loss, is more common than
acute anterior uveitis.
44. Cardiac manifestations
Palpitation & syncope
Heart failure from cardiomyopathy rarely occurs.
Ventricular Arrhythmia is common
Heart block and sudden death may occur.
Approximately 25% of patients may have NCGs at
autopsy, but fewer than 5% have clinical cardiac
disease.
Endomyocardial biopsy low sensitivity but high
specificity but increased risk
Okada et al reported on cardiac infiltration associated
with a novel heterogenous mutation (G481D in
CARD15) in early-onset sarcoidosis.
45.
46. • How to Approach?
• Is biopsy required in all cases?
• Lung or other vital organs biopsy?
53. Diagnosis
The diagnosis is established on the
basis of :
• Clinical finding.
• Radiologic findings.
• Supported by histologic evidence in one or more
organs of noncaseating epithelioid-cell
granulomas in the absence of organisms or
particles.
54.
55. A diagnosis of sarcoidosis is reasonably certain without biopsy in
patients who present with Löfgren's syndrome.
56.
57. Laboratory Studies
Routine lab evaluation often is unrevealing.
Hypercalcemia or hypercalciuria may occur (NCGs secrete 1,25
vitamin D).
Hypercalcemia is seen in about 10-13% of patients, whereas
hypercalciuria is 3 times more common.
An elevated alkaline phosphatase level suggests hepatic
involvement.
Angiotensin converting enzyme (ACE) levels may be elevated.
58. • NCGs secrete ACE, which may function as a cytokine.
• Serum ACE levels are elevated in 60% of patients at the time of diagnosis.
• Levels may be increased in fluid from bronchoalveolar lavage or in CSF.
• Sensitivity and specificity as a diagnostic test is limited (60 and 70%, respectively).
• 14 studies with 4195 patients, SACE Sn=77% (41-100%) and sp=93% (83-99%).
• ACE in CSF is very specific for neuro sarcoidosis.
• There is no clear prognostic value.
• Serum ACE levels may decline in response to therapy.
• Decisions on treatment should not be based on the ACE level alone.
59. Imaging Studies
• A chest radiograph is central to evaluation.
• Routine chest CT scan adds little.
• HRCT of the chest may be helpful.
72. Biopsy specimen
• A biopsy specimen should be obtained from the involved organ that is most
easily accessed, such as the skin, peripheral LN, lacrimal glands, or
conjunctiva.
• If diagnosis requires pulmonary tissue, transbronchial biopsy by means of
bronchoscopy has a diagnostic yield of at least 85% when multiple lung
segments are sampled .
• TBB: yield 60-97%
• EBB: YIELD 60%
• TBNA: Yield 80%
• BAL Lymphocyte >15% sn=90%, sp= low
• Bal cd4:cd8 >3.5 sp=95%, sn= 50-60%
73. The central histologic finding is the presence of NCGs with special
stains negative for fungus and mycobacteria.
74. • Sarcoidal granulomas have no unique
histologic features to differentiate them from
other granulomas.
• Special stains for acid-fast bacilli and fungi,
as well as cultures of such organisms, are
essential.
• If the results of lung biopsy with
bronchoscopy are negative and other organs
are not obviously involved, biopsy of
intrathoracic lymph nodes, which are often
enlarged in patients with sarcoidosis ,may be
necessary to confirm the diagnosis.
85. •Most patients (>75%) require only symptomatic
therapy NSAID.
• Approximately 10% of patients need treatment
for extrapulmonary disease.
•15% of patients require treatment for persistent
pulmonary disease.
86. Corticosteroids are the mainstay of
therapy
• prednisone given daily and then tapered over a 6-month
course is adequate for pulmonary disease.
• Earlier recommendations suggested an initial dose of 1
mg/kg/d of prednisone; however, more recent expert
opinions endorse a lower dose (eg, 40 mg/d), which is
tapered to every other day long-term therapy over several
weeks.
• Most patients who require long-term steroids can be
treated using 10-15 mg of prednisone every other day.
• High-dose inhaled corticosteroids may be an option, but
conclusive data are lacking.
87. • Data suggest that corticosteroid use may be
associated with increased relapse rates.
• Occasionally, certain patients cannot tolerate or
do not respond to corticosteroids.
88. Noncorticosteroid agents
Used more frequently.
Common indications :
• Steroid-resistant disease.
• Intolerable adverse effects.
• patient desire not to take corticosteroids.
89. • Methotrexate (MTX) has been a successful
alternative to prednisone and is a steroid-sparing
agent.
• Chloroquine and hydroxychloroquine are
antimalarial drugs with immunomodulating
properties, which have been used for cutaneous
lesions, hypercalcemia, neurological sarcoidosis,
and bone lesions.
• Chloroquine has also been shown to be
efficacious for the treatment and maintenance of
chronic pulmonary sarcoidosis.
90. Cyclophosphamide has been rarely used with modest
success as a steroid-sparing treatment in patients with refractory
sarcoidosis.
Azathioprine is another second-line therapy, which is best
used as a steroid-sparing agent rather than as a single-drug
treatment for sarcoidosis.
Chlorambucil is an alkylating agent that may be beneficial
in patients with progressive disease unresponsive to
corticosteroids or when corticosteroids are contraindicated.
Cyclosporine is a fungal cyclic polypeptide with
lymphocyte-suppressive properties that may be of limited
benefit in skin sarcoidosis or in progressive sarcoid resistant to
conventional therapy.
91. Infliximab and thalidomide have been used for refractory
sarcoidosis, particularly for cutaneous disease.
Infliximab appears to be an effective treatment for patients with
systemic manifestations such as lupus pernio, uveitis, hepatic
sarcoidosis, and neurosarcoidosis.
Tetracyclines have shown promise for the treatment of cutaneous
sarcoidosis.
92. For pulmonary disease
• Asymptomatic PFT and/or CXR abnormalities are not an indication
for treatment.
• In patients with minimal symptoms, serial reevaluation is prudent.
• Significant respiratory symptoms associated with PFT and CXR
abnormalities likely require therapy.
• For such patients, treatment is indicated if objective evidence of
recent deterioration in lung function exists.
• Corticosteroids can result in small improvements in the functional
vital capacity and in the radiographic appearance in patients with
more severe stage II and III disease.
93. One recent study demonstrated an approach that may
minimize the use of corticosteroids without harming the
patient.
This is accomplished by
• Withholding therapy unless the patient shows at least a 15% decline in
one spirometric measure associated with increasing symptoms or,
• if asymptomatic, withholding therapy unless the patient shows worsening
PFTs and a change in CXR.
94. • For extrapulmonary sarcoidosis involving such critical organs as
the heart, liver, eyes, kidneys, or central nervous system,
corticosteroid therapy is indicated.
• Topical corticosteroids are effective for ocular disease.
• Inhaled corticosteroids are occasionally used, in particular in
patients with endobronchial disease.
95. NSAIDs are indicated for the treatment of arthralgias
and other rheumatic complaints.
Patients with stage I sarcoidosis often require only
occasional treatment with NSAIDs.
96. Further Inpatient Care
• Monitor pulmonary function and CXR every 6-12 months.
• Assess for progression or resolution.
• Determine if previously uninvolved organs have become
affected.
Further Outpatient Care
• Annual slit lamp eye examination and ECG are
recommended.
Follow-up
97. Many patients do not require therapy, and their conditions
will spontaneously improve.
Markers for a poor prognosis include :
Advanced CXR stage.
Extrapulmonary disease (predominantly cardiac and neurologic)
Evidence of pulmonary hypertension.
Multiple studies have demonstrated that the most
important marker for prognosis is the initial CXR stage.
Prognosis
98.
99. Remission
• 2/3 of patients with sarcoidosis generally have a remission within a
decade after diagnosis, with few or no consequences ;remission
occurs for more than half of patients within 3 years .
• Unfortunately, up to 1/3 of patients have progressive disease, leading
to clinically significant organ impairment.
• A recurrence after 1 or more years of remission is uncommon
(affecting <5% of patients), but recurrent disease may develop at any
age and in any organ.
100.
101.
102. Death
• Less than 5% of patients die from sarcoidosis.
• death is usually the result of pulmonary
fibrosis with respiratory failure or of cardiac or
neurologic involvement .